Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1986 Nov;66(2):285–294.

Natural cytotoxic activity in multiple sclerosis patients: defects in IL-2/interferon gamma-regulatory circuit.

E Braakman, A van Tunen, A Meager, C J Lucas
PMCID: PMC1542540  PMID: 2949897

Abstract

In order to determine the factors underlying the impaired natural cytotoxic (NC) activity in multiple sclerosis (MS) patients, we have analysed the interleukin 2 (IL-2)-interferon gamma-(IFN gamma)-NC activity regulatory circuit in 40 MS patients and 40 matched healthy controls. Exogenous recombinant IFN gamma (rIFN gamma) enhanced NC activity in peripheral blood lymphocytes (PBL) derived from MS patients and controls equally well. In contrast, PBL from MS patients showed a significantly lower increase of NC activity in response to IL-2 than healthy controls. This defect in responsiveness was independent of the dose of IL-2. Even at the highest dose of rIL-2 (1000 U/ml), MS patients showed a decreased response. PBL from MS patients required a 2 to 10 times higher dose of IL-2 to reach NC activity levels comparable to controls. In healthy individuals IL-2 can act upon both Fc gamma R+ and Fc gamma R- NC precursor cells. The decreased responsiveness to IL-2 is not confined to one subpopulation of IL-2-responsive precursor cells because depletion of Fc gamma R+ cells before culture in the presence of IL-2 revealed no significant differences in the contribution of Fc gamma R+ precursor cells to the IL-2 enhanced NC activity between MS patients and controls. Also the number of IL-2-responsive precursor cells appeared to be normal since the number of Fc gamma R+ cells in MS patients and controls was comparable. PBL from MS patients produced significantly lower amounts of IFN gamma upon stimulation with IL-2. Analysis of the different parameters of the regulatory circuit at the population level showed, both for patients and controls, a significant correlation between IFN gamma production and increase of NC activity induced by IL-2. Also the endogenous NC activity and IFN gamma production, both in patients and controls, were correlated. At the individual level, defects in NC activity could not be linked to another parameter of the regulatory circuit.

Full text

PDF
285

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benczur M., Petrányl G. G., Pálffy G., Varga M., Tálas M., Kotsy B., Földes I., Hollán S. R. Dysfunction of natural killer cells in multiple sclerosis: a possible pathogenetic factor. Clin Exp Immunol. 1980 Mar;39(3):657–662. [PMC free article] [PubMed] [Google Scholar]
  2. Bloom B. R. Interferons and the immune system. Nature. 1980 Apr 17;284(5757):593–595. doi: 10.1038/284593a0. [DOI] [PubMed] [Google Scholar]
  3. Braakman E., van Tunen A., Meager A., Lucas C. J. IL-2- and IFN gamma-enhanced natural cytotoxic activity: analysis of the role of different lymphoid subsets and implications for activation routes. Cell Immunol. 1986 May;99(2):476–488. doi: 10.1016/0008-8749(86)90255-8. [DOI] [PubMed] [Google Scholar]
  4. Bukowski J. F., Woda B. A., Welsh R. M. Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice. J Virol. 1984 Oct;52(1):119–128. doi: 10.1128/jvi.52.1.119-128.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Burns G. F., Triglia T., Werkmeister J. A. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells. J Immunol. 1984 Sep;133(3):1656–1663. [PubMed] [Google Scholar]
  6. Crane I. J., Leung H., Parti S., Meager A. Ricin-resistant human T-cell hybridomas producing interferon gamma. J Immunol Methods. 1985 Mar 18;77(2):207–218. doi: 10.1016/0022-1759(85)90033-x. [DOI] [PubMed] [Google Scholar]
  7. Devos R., Plaetinck G., Fiers W. Induction of cytolytic cells by pure recombinant human interleukin 2. Eur J Immunol. 1984 Nov;14(11):1057–1060. doi: 10.1002/eji.1830141118. [DOI] [PubMed] [Google Scholar]
  8. Grimm E. A., Robb R. J., Roth J. A., Neckers L. M., Lachman L. B., Wilson D. J., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med. 1983 Oct 1;158(4):1356–1361. doi: 10.1084/jem.158.4.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hauser S. L., Ault K. A., Levin M. J., Garovoy M. R., Weiner H. L. Natural killer cell activity in multiple sclerosis. J Immunol. 1981 Sep;127(3):1114–1117. [PubMed] [Google Scholar]
  10. Herberman R. B., Djeu J., Kay H. D., Ortaldo J. R., Riccardi C., Bonnard G. D., Holden H. T., Fagnani R., Santoni A., Puccetti P. Natural killer cells: characteristics and regulation of activity. Immunol Rev. 1979;44:43–70. doi: 10.1111/j.1600-065x.1979.tb00267.x. [DOI] [PubMed] [Google Scholar]
  11. Johnson R. T., Herndon R. M. Virologic studies of multiple sclerosis and other chronic and relapsing neurological diseases. Prog Med Virol. 1974;18(0):214–228. [PubMed] [Google Scholar]
  12. Kawase I., Brooks C. G., Kuribayashi K., Olabuenaga S., Newman W., Gillis S., Henney C. S. Interleukin 2 induces gamma-interferon production: participation of macrophages and NK-like cells. J Immunol. 1983 Jul;131(1):288–292. [PubMed] [Google Scholar]
  13. Merrill J. E., Gerner R. H., Myers L. W., Ellison G. W. Regulation of natural killer cell cytotoxicity by prostaglandin E in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Part 1. Association between amount of prostaglandin produced, natural killer, and endogenous interferon. J Neuroimmunol. 1983 Jun;4(3):223–237. doi: 10.1016/0165-5728(83)90037-1. [DOI] [PubMed] [Google Scholar]
  14. Merrill J. E., Mohlstrom C., Uittenbogaart C., Kermaniarab V., Ellison G. W., Myers L. W. Response to and production of interleukin 2 by peripheral blood and cerebrospinal fluid lymphocytes of patients with multiple sclerosis. J Immunol. 1984 Oct;133(4):1931–1937. [PubMed] [Google Scholar]
  15. Merrill J. E., Myers L. W., Ellison G. W. Regulation of natural killer cell cytotoxicity by prostaglandin E in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases. Part 2. Effect of exogenous PGE1 on spontaneous and interferon-induced natural killer. J Neuroimmunol. 1983 Jun;4(3):239–251. doi: 10.1016/0165-5728(83)90038-3. [DOI] [PubMed] [Google Scholar]
  16. Merrill J., Jondal M., Seeley J., Ullberg M., Sidén A. Decreased NK killing in patients with multiple sclerosis: an analysis on the level of the single effector cell in peripheral blood and cerebrospinal fluid in relation to the activity in the disease. Clin Exp Immunol. 1982 Feb;47(2):419–430. [PMC free article] [PubMed] [Google Scholar]
  17. Miedema F., Tetteroo P. A., Hesselink W. G., Werner G., Spits H., Melief C. J. Both Fc receptors and lymphocyte-function-associated antigen 1 on human T gamma lymphocytes are required for antibody-dependent cellular cytotoxicity (killer cell activity). Eur J Immunol. 1984 Jun;14(6):518–523. doi: 10.1002/eji.1830140607. [DOI] [PubMed] [Google Scholar]
  18. Neighbour P. A., Bloom B. R. Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci U S A. 1979 Jan;76(1):476–480. doi: 10.1073/pnas.76.1.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Neighbour P. A., Grayzel A. I., Miller A. E. Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis. Clin Exp Immunol. 1982 Jul;49(1):11–21. [PMC free article] [PubMed] [Google Scholar]
  20. Neighbour P. A., Miller A. E., Bloom B. R. Interferon responses of leukocytes in multiple sclerosis. Neurology. 1981 May;31(5):561–566. doi: 10.1212/wnl.31.5.561. [DOI] [PubMed] [Google Scholar]
  21. Ortaldo J. R., Mantovani A., Hobbs D., Rubinstein M., Pestka S., Herberman R. B. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes. Int J Cancer. 1983 Mar 15;31(3):285–289. doi: 10.1002/ijc.2910310306. [DOI] [PubMed] [Google Scholar]
  22. Ortaldo J. R., Mason A. T., Gerard J. P., Henderson L. E., Farrar W., Hopkins R. F., 3rd, Herberman R. B., Rabin H. Effects of natural and recombinant IL 2 on regulation of IFN gamma production and natural killer activity: lack of involvement of the Tac antigen for these immunoregulatory effects. J Immunol. 1984 Aug;133(2):779–783. [PubMed] [Google Scholar]
  23. Rager-Zisman B., Bloom B. R. Natural killer cells in resistance to virus-infected cells. Springer Semin Immunopathol. 1982;4(4):397–414. doi: 10.1007/BF02053741. [DOI] [PubMed] [Google Scholar]
  24. Rauch H. C., Montgomery I. N., Kaplan J. Natural killer cell activity in multiple sclerosis and myasthenia gravis. Immunol Invest. 1985 Oct;14(5):427–434. doi: 10.3109/08820138509047611. [DOI] [PubMed] [Google Scholar]
  25. Santoli D., Hall W., Kastrukoff L., Lisak R. P., Perussia B., Trinchieri G., Koprowski H. Cytotoxic activity and interferon production by lymphocytes from patients with multiple sclerosis. J Immunol. 1981 Apr;126(4):1274–1278. [PubMed] [Google Scholar]
  26. Santoli D., Trinchieri G., Moretta L., Zmijewski C. M., Koprowski H. Spontaneous cell-mediated cytotoxicity in humans. Distribution and characterization of the effector cell. Clin Exp Immunol. 1978 Aug;33(2):309–318. [PMC free article] [PubMed] [Google Scholar]
  27. Silverman S. L., Cathcart E. S. Natural killing in systemic lupus erythematosus: inhibitory effects of serum. Clin Immunol Immunopathol. 1980 Oct;17(2):219–226. doi: 10.1016/0090-1229(80)90090-2. [DOI] [PubMed] [Google Scholar]
  28. Svedersky L. P., Shepard H. M., Spencer S. A., Shalaby M. R., Palladino M. A. Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2. J Immunol. 1984 Aug;133(2):714–718. [PubMed] [Google Scholar]
  29. Trinchieri G., Matsumoto-Kobayashi M., Clark S. C., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984 Oct 1;160(4):1147–1169. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Uchida A., Maida E. M., Lenzhofer R., Micksche M. Natural killer cell activity in patients with multiple sclerosis: interferon and plasmapheresis. Immunobiology. 1982 Feb;160(5):392–402. doi: 10.1016/S0171-2985(82)80003-X. [DOI] [PubMed] [Google Scholar]
  31. Vervliet G., Carton H., Billiau A. Interferon-gamma production by peripheral blood leucocytes from patients with multiple sclerosis and other neurological diseases. Clin Exp Immunol. 1985 Feb;59(2):391–397. [PMC free article] [PubMed] [Google Scholar]
  32. Vervliet G., Carton H., Meulepas E., Billiau A. Interferon production by cultured peripheral leucocytes of MS patients. Clin Exp Immunol. 1984 Oct;58(1):116–126. [PMC free article] [PubMed] [Google Scholar]
  33. Waksman B. Mechanisms in multiple sclerosis. Nature. 1985 Nov 14;318(6042):104–105. doi: 10.1038/318104a0. [DOI] [PubMed] [Google Scholar]
  34. Zander H., Abb J., Kaudewitz P., Riethmüller G. Natural killing activity and interferon production in multiple sclerosis. Lancet. 1982 Jan 30;1(8266):280–280. doi: 10.1016/s0140-6736(82)91001-7. [DOI] [PubMed] [Google Scholar]
  35. Zöller M., Wigzell H. Normally occurring inhibitory cells for natural killer cell activity. II. Characterization of the inhibitory cell. Cell Immunol. 1982 Nov 15;74(1):27–39. doi: 10.1016/0008-8749(82)90003-x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES